Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 6/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.66 |
| ▸ | NPC1 | O15118 | 8/20 | 0.64 |
| ▸ | RAB9A | P51151 | 7/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.64 |
| ▸ | HPGD | P15428 | 2/20 | 0.64 |
| ▸ | MAPT | P10636 | 9/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.61 |
| ▸ | GAA | P10253 | 3/20 | 0.59 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
| ▸ | HTT | P42858 | 2/20 | 0.54 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2061371 | 1.00 | MEN1 (0.66) | MEN1KMT2ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL10974048 | 0.88 | ALDH1A1 (0.62) | MEN1KMT2ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL8392815 | 0.87 | MEN1 (0.55) | MEN1KMT2ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL10624822 | 0.84 | NPC1 (0.86) | MEN1KMT2ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL2061754 | 0.84 | ALOX5 (0.77) | MEN1KMT2ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL2633343 | 0.84 | ALOX5 (0.77) | MEN1KMT2ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1984342 | 0.84 | KMT2A (0.69) | MEN1KMT2ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL10311765 | 0.84 | NPC1 (0.58) | MEN1KMT2ANPC1RAB9ASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL9423776 | 0.83 | ALOX5 (0.75) | MEN1KMT2ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL16587382 | 0.83 | MAPT (0.75) | MEN1KMT2ASMN1; SMN2ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230226195-A1 | TARGETED ABERRANT ALPHA-SYNUCLEIN SPECIES AND INDUCED UBIQUITINATION AND PROTEOSOMAL CLEARANCE VIA CO-RECRUITMENT OF AN E3-LIGASE SYSTEM | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-07-20 | — | — | US | disclosed |
| EP-4168441-A1 | TARGETED ABERRANT ALPHA-SYNUCLEIN SPECIES AND INDUCED UBIQUITINATION AND PROTEOSOMAL CLEARANCE VIA CO-RECRUITMENT OF AN E3-LIGASE SYSTEM | Dana-Farber Cancer Institute, Inc. (US) | 2023-04-26 | — | — | EP | disclosed |
| WO-2021257650-A1 | TARGETED ABERRANT ALPHA-SYNUCLEIN SPECIES AND INDUCED UBIQUITINATION AND PROTEOSOMAL CLEARANCE VIA CO-RECRUITMENT OF AN E3-LIGASE SYSTEM | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-12-23 | — | — | WO | disclosed |
| US-9833458-B2 | Thioflavin derivatives for use in the antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2017-12-05 | — | — | US | disclosed |
| US-9808541-B2 | Thioflavin derivatives for use in antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition | University of Pittsburgh—Of the Commonwealth System of Higher Eduation (US) | 2017-11-07 | — | — | US | disclosed |
| US-9134328-B2 | Methods of using benzothiazole derivative compounds and compositions | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2015-09-15 | — | — | US | disclosed |
| US-9133143-B2 | (3-fluoro-2-hydroxy)propyl-functionalized aryl derivatives or pharmaceutically acceptable salts thereof, method for preparing same, and pharmaceutical composition containing same as active ingredient for the diagnosis or treatment of neurodegenerative brain diseases | FUTURECHEM CO., LTD. (KR) | 2015-09-15 | — | — | US | disclosed |
| US-9133143-B2 | (3-fluoro-2-hydroxy)propyl-functionalized aryl derivatives or pharmaceutically acceptable salts thereof, method for preparing same, and pharmaceutical composition containing same as active ingredient for the diagnosis or treatment of neurodegenerative brain diseases | FUTURECHEM CO., LTD. (KR) | 2015-09-15 | — | — | US | disclosed |
| US-20150190400-A1 | THIOFLAVIN DERIVATIVES FOR USE IN THE ANTEMORTEM DIAGNOSIS OF ALZHEIMER'S DISEASE AND IN VIVO IMAGING AND PREVENTION OF AMYLOID DEPOSITION | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2015-07-09 | — | — | US | disclosed |
| US-20150165073-A1 | THIOFLAVIN DERIVATIVES FOR USE IN ANTEMORTEM DIAGNOSIS OF ALZHEIMER'S DISEASE AND IN VIVO IMAGING AND PREVENTION OF AMYLOID DEPOSITION | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2015-06-18 | — | — | US | disclosed |
| US-20080219931-A1 | Amyloid Imaging as a Surrogate Marker for Efficacy of Anti-Amyloid Therapies | UNIVERSITY OF PITTSBURGH | 2008-09-11 | — | — | US | disclosed |
| US-20080154042-A1 | THIOFLAVIN DERIVATIVES FOR USE IN THE ANTEMORTEM DIAGNOSIS OF ALZHEIMERS DISEASE AND IN VIVO IMAGING AND PREVENTION OF AMYLOID DEPOSITION | UNIVERSITY OF PITTSBURGH | 2008-06-26 | — | — | US | disclosed |
| US-20080154042-A1 | THIOFLAVIN DERIVATIVES FOR USE IN THE ANTEMORTEM DIAGNOSIS OF ALZHEIMERS DISEASE AND IN VIVO IMAGING AND PREVENTION OF AMYLOID DEPOSITION | UNIVERSITY OF PITTSBURGH | 2008-06-26 | — | — | US | disclosed |
| US-7351401-B2 | Thioflavin derivatives for use in the antemortem diagnosis of Alzheimers disease and in vivo imaging and prevention of amyloid deposition | UNIVERSITY OF PITTSBURGH (US) | 2008-04-01 | — | — | US | disclosed |
| US-7351401-B2 | Thioflavin derivatives for use in the antemortem diagnosis of Alzheimers disease and in vivo imaging and prevention of amyloid deposition | UNIVERSITY OF PITTSBURGH (US) | 2008-04-01 | — | — | US | disclosed |
| US-20080021077-A1 | Bioavailability, nontoxic; 2-(3'-Iodo-4'-aminophenyl)-6-methoxybenzothiazole | UNIVERSITY OF PITTSBURGH | 2008-01-24 | — | — | US | disclosed |
| US-20080021077-A1 | Bioavailability, nontoxic; 2-(3'-Iodo-4'-aminophenyl)-6-methoxybenzothiazole | UNIVERSITY OF PITTSBURGH | 2008-01-24 | — | — | US | disclosed |
| US-7270800-B2 | Imaging amyloid deposits in living patients, with an amyloid binding agents having radiolabeled iodine; radiotherapy | UNIVERSITY OF PITTSBURGH (US) | 2007-09-18 | — | — | US | disclosed |
| US-7270800-B2 | Imaging amyloid deposits in living patients, with an amyloid binding agents having radiolabeled iodine; radiotherapy | UNIVERSITY OF PITTSBURGH (US) | 2007-09-18 | — | — | US | disclosed |
| WO-2007035405-A2 | IN-VIVO AND IN-VITRO METHOD FOR DETECTING AMYLOID DEPOSITS HAVING AT LEAST ONE AMYLOIDOGENIC PROTEIN | UNIVERSITY OF PITTSBURGH (US) | 2007-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080154042-A1 | THIOFLAVIN DERIVATIVES FOR USE IN THE ANTEMORTEM DIAGNOSIS OF ALZHEIMERS DISEASE AND IN VIVO IMAGING AND PREVENTION OF AMYLOID DEPOSITION | APP, PSEN2, MAPT | MEN1 2842/4885KMT2A 3801/4885NPC1 300/4885 |
| US-20150165073-A1 | THIOFLAVIN DERIVATIVES FOR USE IN ANTEMORTEM DIAGNOSIS OF ALZHEIMER'S DISEASE AND IN VIVO IMAGING AND PREVENTION OF AMYLOID DEPOSITION | APP, PSEN2, MAPT | MEN1 2922/4885KMT2A 3827/4885NPC1 320/4885 |
| US-20150190400-A1 | THIOFLAVIN DERIVATIVES FOR USE IN THE ANTEMORTEM DIAGNOSIS OF ALZHEIMER'S DISEASE AND IN VIVO IMAGING AND PREVENTION OF AMYLOID DEPOSITION | APP, PSEN2, MAPT | MEN1 2819/4885KMT2A 3728/4885NPC1 273/4885 |
| US-20230226195-A1 | TARGETED ABERRANT ALPHA-SYNUCLEIN SPECIES AND INDUCED UBIQUITINATION AND PROTEOSOMAL CLEARANCE VIA CO-RECRUITMENT OF AN E3-LIGASE SYSTEM | SNCA, ADRM1, UBE3C | MEN1 4306/4885KMT2A 2586/4885NPC1 1139/4885 |
| US-20080021077-A1 | Bioavailability, nontoxic; 2-(3'-Iodo-4'-aminophenyl)-6-methoxybenzothiazole | APOL1, APOB, APP | MEN1 1843/4885KMT2A 3425/4885NPC1 30/4885 |
| US-20080219931-A1 | Amyloid Imaging as a Surrogate Marker for Efficacy of Anti-Amyloid Therapies | TTR, APP, SAAL1 | MEN1 582/4885KMT2A 4494/4885NPC1 332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.